Welcome to the seventeenth edition of the rare disease newsletter. A few months has changed the world of clinical research into a very different place. This issue includes a summary of work PRA has done to understand the impact of COVID19 on the rare disease patient community and to rare disease research.
PRA’s Vaccine Solutions group understands the unique challenges and characteristics of vaccine development. Right from the start, our experts will…
Early Engagement Crucial to Develop Trial Design for Accelerated Schedule Vaccine Study
A case study describing PRA's involvement in an accelerated schedule vaccine study for poliomyelitis.
Are We There Yet? - Beyond the Target Product Profile
In the previous blog, we looked at the concept of the Target Product Profile (TPP). At one level, the TPP can be thought of as a document that sets…